PhaseBio Pharmaceuticals, Inc. – NASDAQ:PHAS

PhaseBio Pharmaceuticals stock price today

$0.07
+0.05
+312.35%
Financial Health
0
1
2
3
4
5
6
7
8
9

PhaseBio Pharmaceuticals stock price monthly change

-75.75%
month

PhaseBio Pharmaceuticals stock price quarterly change

-98.01%
quarter

PhaseBio Pharmaceuticals stock price yearly change

-99.33%
year

PhaseBio Pharmaceuticals key metrics

Market Cap
N/A
Enterprise value
1.01M
P/E
-0.02
EV/Sales
-0.10
EV/EBITDA
0.03
Price/Sales
-0.34
Price/Book
-0.02
PEG ratio
N/A
EPS
0.59
Revenue
818K
EBITDA
28.16M
Income
27.83M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
-280.94%
Oper. margin
1041.79%
Gross margin
-2.08%
EBIT margin
1041.79%
EBITDA margin
3443.23%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

PhaseBio Pharmaceuticals stock price history

PhaseBio Pharmaceuticals stock forecast

PhaseBio Pharmaceuticals financial statements

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Profit margin
Sep 2021 335K -31.92M -9529.55%
Dec 2021 158K 87.82M 55588.56%
Mar 2022 117K -11.28M -9648.72%
Jun 2022 208K -16.78M -8067.79%
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Earnings per share (EPS)
2022-05-16 -0.66 -0.23
2022-08-12 -0.31 -0.34
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Debt to assets
Sep 2021 77725000 128.05M 164.75%
Dec 2021 60540000 153.57M 253.67%
Mar 2022 38664000 141.05M 364.83%
Jun 2022 22166000 139.56M 629.63%
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Cash Flow
Sep 2021 -6.13M -638K -1.32M
Dec 2021 -19.99M -1.65M 7.09M
Mar 2022 -22.88M -49K -179K
Jun 2022 -10.41M -58K -415K

PhaseBio Pharmaceuticals alternative data

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Employee count
Aug 2023 60
Sep 2023 60
Oct 2023 60
Nov 2023 60
Dec 2023 60
Jan 2024 60
Feb 2024 60
Mar 2024 60
Apr 2024 60
May 2024 60
Jun 2024 60
Jul 2024 60

PhaseBio Pharmaceuticals other data

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS): Insider trades (number of shares)
Period Buy Sel
Nov 2021 0 5766
May 2022 0 11248
Oct 2022 0 1784109
Transaction Date Insider Security Shares Price per share Total value Source
Option
VAN DEN BROEK RICHARD director
Restricted Stock Units 3,750 N/A N/A
Option
THORP CLAY director
Common Stock 3,750 N/A N/A
Option
THORP CLAY director
Restricted Stock Units 3,750 N/A N/A
Option
HUMPHRIES WILLIAM D. director
Common Stock 2,538 N/A N/A
Option
HUMPHRIES WILLIAM D. director
Restricted Stock Units 2,538 N/A N/A
Option
HARRIGAN EDMUND director
Common Stock 3,750 N/A N/A
Option
SAPIR ALEX director
Common Stock 3,750 N/A N/A
Option
HUTSON NANCY J director
Restricted Stock Units 3,750 N/A N/A
Option
HUTSON NANCY J director
Common Stock 3,750 N/A N/A
Option
HARRIGAN EDMUND director
Restricted Stock Units 3,750 N/A N/A
Patent
Grant
Filling date: 22 Jun 2020 Issue date: 8 Mar 2022
Application
Filling date: 1 Jul 2021 Issue date: 27 Jan 2022
Application
Filling date: 31 Aug 2021 Issue date: 13 Jan 2022
Application
Filling date: 20 Sep 2019 Issue date: 11 Nov 2021
Application
Filling date: 17 Jun 2021 Issue date: 21 Oct 2021
Grant
Filling date: 17 Jan 2020 Issue date: 5 Oct 2021
Grant
Filling date: 8 May 2015 Issue date: 6 Jul 2021
Grant
Filling date: 7 Sep 2018 Issue date: 22 Jun 2021
Application
Filling date: 22 Jun 2020 Issue date: 11 Mar 2021
Grant
Filling date: 26 Sep 2016 Issue date: 9 Mar 2021
Monday, 24 October 2022
businesswire.com
businesswire.com
Monday, 17 October 2022
24/7 Wall Street
Friday, 12 August 2022
Zacks Investment Research
Monday, 16 May 2022
Zacks Investment Research
Tuesday, 21 December 2021
Benzinga
Monday, 15 November 2021
Benzinga
Wednesday, 10 November 2021
Zacks Investment Research
Wednesday, 3 November 2021
Benzinga
Sunday, 31 October 2021
PennyStocks
Thursday, 7 October 2021
Zacks Investment Research
Tuesday, 31 August 2021
Business Wire
  • What's the price of PhaseBio Pharmaceuticals stock today?

    One share of PhaseBio Pharmaceuticals stock can currently be purchased for approximately $0.07.

  • When is PhaseBio Pharmaceuticals's next earnings date?

    Unfortunately, PhaseBio Pharmaceuticals's (PHAS) next earnings date is currently unknown.

  • Does PhaseBio Pharmaceuticals pay dividends?

    No, PhaseBio Pharmaceuticals does not pay dividends.

  • What is PhaseBio Pharmaceuticals's stock symbol?

    PhaseBio Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "PHAS".

  • What is PhaseBio Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of PhaseBio Pharmaceuticals?

    Shares of PhaseBio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are PhaseBio Pharmaceuticals's key executives?

    PhaseBio Pharmaceuticals's management team includes the following people:

    • Mr. Jonathan P. Mow Pres, Chief Executive Officer & Director(age: 60, pay: $812,440)
    • Dr. John S. Lee Chief Medical Officer(age: 57, pay: $582,230)
    • Mr. John P. Sharp Chief Financial Officer(age: 60, pay: $516,420)
  • How many employees does PhaseBio Pharmaceuticals have?

    As Jul 2024, PhaseBio Pharmaceuticals employs 60 workers.

  • When PhaseBio Pharmaceuticals went public?

    PhaseBio Pharmaceuticals, Inc. is publicly traded company for more then 6 years since IPO on 18 Oct 2018.

  • What is PhaseBio Pharmaceuticals's official website?

    The official website for PhaseBio Pharmaceuticals is phasebio.com.

  • Where are PhaseBio Pharmaceuticals's headquarters?

    PhaseBio Pharmaceuticals is headquartered at 1 Great Valley Pkwy Ste 30, Malvern, PENNSYLVANIA.

  • How can i contact PhaseBio Pharmaceuticals?

    PhaseBio Pharmaceuticals's mailing address is 1 Great Valley Pkwy Ste 30, Malvern, PENNSYLVANIA and company can be reached via phone at +1 610 981 6500.

PhaseBio Pharmaceuticals company profile:

PhaseBio Pharmaceuticals, Inc.

phasebio.com
Exchange:

NASDAQ

Full time employees:

60

Industry:

Biotechnology

Sector:

Healthcare

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

1 Great Valley Pkwy Ste 30
Malvern, PENNSYLVANIA 19355

CIK: 0001169245
ISIN: US7172241090
CUSIP: 717224109